Search results
The incidence of lung cancer and therefore its related mortality can be reduced by early detection, treatment of disease, chemoprevention, and smoking avoidance and cessation. 261 Of these, only smoking prevention and cessation programs aimed at reducing smoking rates have been shown to reduce lung cancer risk. Prevention of smoking initiation ...
- Lung Cancer Screening: Review and 2021 Update - PMC
Lung cancer screening with low-dose CT (LDCT) scans has been...
- Lung Cancer Screening: Review and 2021 Update - PMC
Simulation studies suggest that risk prediction models to determine eligibility for lung cancer screening could be associated with reduced lung cancer deaths and the number of participants needed to screen to prevent 1 lung cancer death.
27 lut 2021 · Lung cancer (LC) is the leading cause of cancer death. Barriers to the early presentation for LC include lack of symptom awareness, symptom misappraisal, poor relationship with doctors and lack of access to healthcare services. Addressing such barriers can help detect LC early. This systematic review describes the effect of recent interventions ...
2 kwi 2022 · Lung cancer screening with low-dose CT (LDCT) scans has been widely accepted within the last decade. Our knowledge and ability to implement screening has greatly increased because of significant research efforts and guidelines from multiple professional societies.
4 sie 2023 · Lung cancer screening has been demonstrated to reduce lung cancer mortality, but its benefits must be weighed against the potential harms of unnecessary procedures, false-positive radiological findings, and overdiagnosis. Individuals at highest risk of lung cancer are more likely to maximize benefits while minimizing harm from screening.
Key points. •. Achieving smoking abstinence in the lung cancer screening setting or after cancer diagnosis improves health outcomes. •. Clinicians should actively engage in efforts to minimize stigma associated with continued smoking, especially after the diagnosis of cancer. •.
Preclinical work has demonstrated anti-interleukin-1beta (IL-1B) can delay the progression of precancers into invasive lung adenocarcinomas. Canakinumab, a humanized anti-ILB antibody has been reported to decrease lung cancer incidence by ∼70% in CANTOS trial. Can-Prevent-Lung is single arm Phase II trial aiming to test whether canakinumab can increase regression rate of persistent high-risk ...
